News
Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy ...
Sarepta Therapeutics now trades at book value with strong cash and cost-cutting plans, while ELEVIDYS may regain broader use.
Fintel on MSN4d
Oppenheimer Upgrades Sarepta Therapeutics (SRPT)Fintel reports that on July 29, 2025, Oppenheimer upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second ...
The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.
Sarepta Therapeutics announced it has laid off more than one-third of its workforce, a drastic cost-cutting move following ...
Zacks Investment Research on MSN3d
Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings GrowthWall Street expects a year-over-year increase in earnings on higher revenues when Sarepta Therapeutics (SRPT) reports results ...
The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening financial situation.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback